Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.
Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics.
Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).
Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.
Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours.
Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.
Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.
Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.